Clinical-stage precision-medicine biotechnology company developing small-molecule therapies for rare genetic diseases and related expansion indications
Clinical-stage precision-medicine biotechnology company developing small-molecule therapies for rare genetic diseases and related expansion indications. Its lead TRPV4 inhibitor, STAR-0871, is being developed for Charcot-Marie-Tooth disease type 2C and overactive bladder, with discovery programs in genetic epilepsy and other CNS disorders.